

Supplemental Table S4:

KRAS mutation analysis by WTB-HRM of human colon tissue specimens and control sequencing of HRM products.

Patient No.	Histological finding	HRM result ^d	Control sequencing result after HRM ^e
C93	Carcinoma (pT1) ^a	MT	MT (<i>KRAS</i> c.35G>A, p.G12D)
C40	Adenoma	WT	WT
C42	Adenoma	WT	WT
C80	Adenoma	WT	WT
C81	Adenoma	WT	WT
C82	Adenoma	WT	WT
C83	Adenoma	WT	WT
C84	Adenoma	WT	WT
C86	Adenoma	WT	WT
C87	Adenoma, advanced ^b	WT	WT
C88	Adenoma, advanced	WT	WT
C90	Adenoma	MT	MT (<i>KRAS</i> c.35G>T, p.G12V)
C91	Adenoma, advanced	MT	MT (<i>KRAS</i> c.35G>A, p.G12D)
C92	Adenoma, advanced	MT	MT (<i>KRAS</i> c.35G>A, p.G12D)
C94	Adenoma	WT	WT
C95	Adenoma	WT	WT
C96	Adenoma	WT	WT
C97	Adenoma	WT	WT
C98	Adenoma	WT	WT
C44	Serrated lesion ^c	MT	MT (<i>KRAS</i> c.35G>A, p.G12D)

^a Classification according to the Union internationale contre le cancer (UICC)

^b Advanced adenomas are those with a diameter of ≥ 1 cm and/or (tubulo)villous histology and/or with high grade dysplasia and/or ≥ 3 adenomas detected at the same colonic examination.

^c Patient with multiple hyperplastic polyps

^d MT mutation; WT wild-type

^e Nomenclature of mutations according to guidelines of the Human Genome Variation Society